Latest Sarissa Capital Management LP Stock Portfolio
Sarissa Capital Management LP Performance:
2024 Q4: -1.33%YTD: -23.64%2023: 3.51%
Performance for 2024 Q4 is -1.33%, and YTD is -23.64%, and 2023 is 3.51%.
About Sarissa Capital Management LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Sarissa Capital Management LP reported an equity portfolio of $322.9 Millions as of 31 Dec, 2024.
The top stock holdings of Sarissa Capital Management LP are INVA, IRWD, NBIX. The fund has invested 39.1% of it's portfolio in INNOVIVA INC and 22.5% of portfolio in IRONWOOD PHARMACEUTICALS INC.
The fund managers got completely rid off BIOGEN INC (BIIB) and REGULUS THERAPEUTICS INC (RGLS) stocks. They significantly reduced their stock positions in GILEAD SCIENCES INC (GILD), CYTOKINETICS INC (CYTK) and NEUROCRINE BIOSCIENCES INC (NBIX). The fund showed a lot of confidence in some stocks as they added substantially to LANTHEUS HLDGS INC (LNTH).
The top stock holdings of Sarissa Capital Management LP are INVA, IRWD, NBIX. The fund has invested 39.1% of it's portfolio in INNOVIVA INC and 22.5% of portfolio in IRONWOOD PHARMACEUTICALS INC.
The fund managers got completely rid off BIOGEN INC (BIIB) and REGULUS THERAPEUTICS INC (RGLS) stocks. They significantly reduced their stock positions in GILEAD SCIENCES INC (GILD), CYTOKINETICS INC (CYTK) and NEUROCRINE BIOSCIENCES INC (NBIX). The fund showed a lot of confidence in some stocks as they added substantially to LANTHEUS HLDGS INC (LNTH).
Sarissa Capital Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Sarissa Capital Management LP made a return of -1.33% in the last quarter. In trailing 12 months, it's portfolio return was -23.64%.
New Buys
Additions
| Ticker | % Inc. |
|---|---|
| lantheus hldgs inc | 142 |
Additions to existing portfolio by Sarissa Capital Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| gilead sciences inc | -65.67 |
| cytokinetics inc | -24.88 |
| neurocrine biosciences inc | -24.69 |
Sarissa Capital Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| regulus therapeutics inc | -290,737 |
| biogen inc | -5,223,990 |
Sarissa Capital Management LP got rid off the above stocks
Sector Distribution
Sarissa Capital Management LP has about 100% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 100 |
Market Cap. Distribution
Sarissa Capital Management LP has about 20.6% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 61.6 |
| LARGE-CAP | 20.6 |
| MID-CAP | 13.9 |
| MICRO-CAP | 3.9 |
Stocks belong to which Index?
About 83.2% of the stocks held by Sarissa Capital Management LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 75.7 |
| Others | 16.8 |
| S&P 500 | 7.5 |
Sarissa Capital Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Sarissa Capital Management LP
Sarissa Capital Management LP has 8 stocks in it's portfolio. INVA proved to be the most loss making stock for the portfolio. NBIX was the most profitable stock for Sarissa Capital Management LP last quarter.
Last Reported on: 14 Feb, 2025| Ticker | Namesorted descending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| INVA | innoviva inc | 39.10 | 7,277,000 | 126,256,000 | unchanged | 0.00 | ||
Historical Trend of INNOVIVA INC Position Held By Sarissa Capital Management LPWhat % of Portfolio is INVA?:Number of INVA shares held:Change in No. of Shares Held: | ||||||||
| IRWD | ironwood pharmaceuticals inc | 22.49 | 16,390,000 | 72,607,700 | unchanged | 0.00 | ||
| NBIX | neurocrine biosciences inc | 13.07 | 309,116 | 42,194,300 | reduced | -24.69 | ||
| CYTK | cytokinetics inc | 12.15 | 833,799 | 39,221,900 | reduced | -24.88 | ||
| GILD | gilead sciences inc | 7.50 | 262,080 | 24,208,300 | reduced | -65.67 | ||
| AMRN | amarin corp plc | 3.73 | 24,850,600 | 12,052,600 | unchanged | 0.00 | ||
| LNTH | lantheus hldgs inc | 1.75 | 63,000 | 5,635,980 | added | 142 | ||
| VOR | vor biopharma inc | 0.21 | 618,000 | 685,980 | unchanged | 0.00 | ||
| RGLS | regulus therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BIIB | biogen inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
